Moderna Stock Price Today: Moderna shares skyrocketed roughly 85% to 95% in pre-market and early trading, nearly doubling in value after Moderna and partner Merck reported positive Phase 3 results for their personalized mRNA skin-cancer vaccine. Here’s what investors should watch in the Moderna Stock Price today.
Moderna Stock Price Today: Moderna Stock Rises Higher
Moderna shares rocketed over 80% higher today, trading at $115.06 following groundbreaking late-stage clinical trial results for its personalized mRNA skin-cancer vaccine. This monumental surge represents the first-ever successful final-stage study for any mRNA-based cancer therapy, positioning Moderna to aggressively diversify its business beyond its declining COVID-19 franchise.
Moderna Stock Price Today: Cancer Vaccine Trial Breakthrough
Moderna, in partnership with Merck (MRK), released highly anticipated interim data from its Phase 3 INTerpath-001 trial:
-
The Treatment: Intismeran autogene (mRNA-4157), a made-to-order vaccine tailored to mutations in each patient’s individual tumor, administered alongside Merck’s blockbuster immunotherapy drug Keytruda.
-
The Milestones: The combo reached its primary endpoint of recurrence-free survival in 1,137 high-risk melanoma patients, significantly extending the time individuals lived without cancer returning.
-
Metastasis Reduction: It achieved its key secondary endpoint by significantly reducing the risk of cancer spreading to other parts of the body.
-
Safety Profile: Investigators reported no new safety concerns during the trial.
Moderna Stock Price Today: Strategic Impact & Valuation in Market
-
The Partner Wins Too: Shares of Merck also jumped 6.5% to 8%, hitting all-time highs as the success extends the commercial longevity of Keytruda.
-
Revenue Diversification: With COVID-19-related sales tapering off, Barclays analysts estimate this specific skin cancer vaccine alone could yield $3 billion in annual sales by 2035.
-
The Next Chapter: This data validates Moderna’s multi-year pivot toward oncology and rare diseases. The program is already being actively tested across other aggressive tumor types, including lung, bladder, and kidney cancers.
Moderna Stock Price Today: What Investors Should Know Next
Moderna and Merck announced plans to discuss these interim findings with global health regulators immediately to file for marketing approval.
As the vaccine is entirely customized for individual patients, investors must watch how automated processes handle mass manufacturing and profit margins moving forward.
Later this year, Wall Street will closely monitor Phase 2 trial readouts for renal cell carcinoma (kidney cancer) to determine if the platform’s efficacy easily replicates across other major cancer types.
